Pancreatic adenocarcinoma is a frequent and severe disease, either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic carcinoma (LAPC). Though no improvement in patients outcome have been made between 1996 and 2011, since 5 years new treatment options have become available to treat our patients. New standard first line regimens, such as FOLFIRINOX and gemcitabine combined with nab-paclitaxel, have improved overall survivals and second line treatments have been tested and validated. Other first-line treatments have failed, but research remains active and trials are ongoing with promising new anti-cancer agents. These new effective regimens used for MPA have yielded promising results in LAPC patients in open cohorts or phase II trials and a recent trial have failed to demonstrate the added value of classical external radiotherapy in this setting. Here, we review current standards of care in LAPC and MPA, consider the latest challenges and strategic questions, and examine what we may hope for in the future.
Introduction
Pancreatic adenocarcinoma (PA) is a frequent disease, with 80% of patients ineligible for potential curative resection at diagnosis. In these cases, PA is either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic carcinoma (LAPC). PA is currently the fifth cause of cancer-related death in Europe with an overall 5-year survival rate of only about 6% [1] . Before 2011, gemcitabine was the only approved chemotherapy for MPA and LAPC, with median survival of approximately 7 and 19 months, respectively, and few other treatment options after gemcitabine failure.
Since 2011, new chemotherapeutic regimens have proven effective in first-line treatment of MPA, thus offering multiple standard possibilities in this setting and raising new strategic questions on the best treatment sequence. Other first-line treatments have failed, but some trials are still ongoing with promising anti-cancer agents. These new effective first-line treatments have improved patient survival, and now second-line chemotherapies, which 10 years ago were thought to be unrealistic, have been developed using different regimens considered as standards. However, the current literature reveals contradictory results on treatment efficacy and tolerability.
Important studies of LAPC have tested the addition of tyrosine kinase inhibitors to gemcitabine and the benefit of radiotherapy. New effective regimens used for MPA have yielded promising results in LAPC patients in open cohorts or phase II trials. Here, we review current standards of care in LAPC and MPA, consider the latest challenges and strategic questions, and examine what we may hope for in the future.
Locally advanced pancreatic adenocarcinoma How to define LAPC?
Very simply, a non-metastatic PA that is not resectable should be considered as an LAPC, even if many controversies are ongoing regarding the definition of this patient subgroup.
Patients with LAPC represent approximately 30% of all pancreatic cancer patients at the time of diagnosis and have a prognosis intermediate between those with resectable disease and those with metastatic disease, with a median overall survival (OS) generally ranging from 9 to 32 months [2] [3] [4] [5] .
Several definitions have been proposed for LAPC. They differ mainly in terms of the extent of the tumor with regional vessels (superior mesenteric artery, celiac axis, common hepatic artery, portal vein, and superior mesenteric vein). The most commonly used criteria are those of the National Comprehensive Cancer Network and the joint consensus conference of the Americas Hepato-Pancreato-Biliary Association [6] , which differentiate resectable, borderline, and locally advanced tumors, in nonmetastatic PA patients. Due to complexities and variations involved in making these distinctions, it is very important that all cases of non-metastatic pancreatic cancer are discussed by a multidisciplinary team in high-volume centers. Table 1 summarizes the criteria of borderline and locally advanced tumors of the pancreas according to the National Comprehensive Cancer Network and the Americas HepatoPancreato-Biliary Association.
Is there a place for radiation therapy in LAPC?
In a meta-analysis of 23 trials including 147 patients with unresectable non-metastatic pancreatic cancer [7] , first-line treatment (chemotherapy or chemoradiotherapy [CRT]) led to an objective response in 35% of patients and disease stabilization in 41.6%. Secondary surgery was possible in 33.2% with R0 margins in 79.2% of the resected patients. Therefore, approximately onethird of initially staged non-resectable tumor patients were operated following induction therapy, with survival rates comparable to those of patients with initially resectable disease. This shows that the challenge in LAPC patients is not only to increase survival, with quality of life preservation, but also to convert some patients to surgery with a curative intent.
Various studies with heterogeneous treatment schedules assessing chemotherapy alone or combined with radiotherapy have been performed for LAPC and borderline tumors. Radiotherapy may improve patient outcome, tumor response, and potentially secondary surgery, and, if not, may also allow for chemotherapy holidays, which are often requested by patients after several months of anti-cancer treatment.
In the early 2000's, CRT was compared to the best supportive care and showed a survival benefit in a phase III trial, with increased toxicity in the CRT arm [8] . A systematic review of the management of LAPC using radiation 6 chemotherapy including 11 trials with 794 patients, published approximately 10 years ago, suggested that CRT was superior to radiotherapy alone, but CRT followed by chemotherapy did not provide any survival advantage over chemotherapy alone [9] .
The important FFCD-SFRO 2000-01 phase III study then showed that upfront gemcitabine did better than CRT (combined with 5-fluorouracil and cisplatin) followed by gemcitabine (median OS of 14.5 versus 8 months, respectively, P ¼ 0.014) [10] . These results suggested that most LAPC patients are in fact metastatic, but without metastases detectable by imaging, at the time of treatment start. This trial clearly showed that starting with CRT is not a good option, but failed to demonstrate the potential added value of CRT after induction chemotherapy. Other studies have suggested that CRT with capecitabine may be preferable to CRT with gemcitabine [11] . A new trial with a modern induction chemotherapy regimen and testing an additional novel radiosensitizer, nelfinavir plus gemcitabine, is currently ongoing (NCT01086332).
A pooled retrospective analysis of two prospective trials evaluated CRT in LAPC after initial chemotherapy with gemcitabine for 3 months. Among patients with non-progressive disease (70.3%), 44% followed the same chemotherapy and 56% received CRT. Patients treated with CRT had better progression-free survival (PFS) (10.8 months versus 7.4 months, P ¼ 0.005) and OS (15 months versus 11.7 months, P ¼ 0.0009) [12] .
These results led to the recently published LAP07 phase III trial [13] , which was designed to answer two questions: (1) What benefit can erlotinib add to gemcitabine in the LAPC setting? and, (2) Does CRT improve OS in the case of disease control after 4 months of induction by gemcitabine? Patients with LAPC were first randomized to gemcitabine alone or gemcitabine plus erlotinib. In a second randomization involving patients without disease progression after 4 months, patients received either two additional months of the same chemotherapy regimen or CRT (54 Gy plus capecitabine). The median OS from the date of the first randomization was not significantly different between chemotherapy (16.5 months) and CRT (15.2 months, hazard ratio [HR]: 1.03; P ¼ 0.83) and between gemcitabine alone (13.6 months) or combined with erlotinib (11.9 months, HR: 1.19; P ¼ 0.09). CRT was associated with a decreased rate of local progression (32% versus 46%, P ¼ 0.03) and no increase in grade 3-4 toxicities, except for nausea.
We will also have to consider the place of radiation therapy in the light of improvement of radiation techniques [14] . Indeed, intensity-modulated radiation therapy [15] , dose escalation [16] , and stereotactic body radiotherapy [17, 18] seem to result in a higher response rate, R0 resection rate, and recurrence-free survival in preliminary retrospective studies. Considering all these results, the addition of CRT did not improve patient survival outcomes and the standard of care in LAPC in 2017 remains chemotherapy with gemcitabine, as recommended in the most recent guidelines [19] . However, as a minor role of CRT in LAPC has been observed, it could be an individual option in selected patients [19] . We need to define this subgroup better in the light of optimized induction chemotherapy as FOLFIRINOX and also test improved techniques of radiation therapy, as in the ongoing RTOG 1201 trial (NCT01921751).
What's next?
The FOLFIRINOX regimen has become a reference treatment for MPA in patients under 75 years old, with good performance status (PS) and normal bilirubin level since 2011 [20] . Because of reported response rates exceeding 30%, this regimen was then evaluated in patients with LAPC, in the hope of downstaging for secondary resection. Many studies have recently been published with similar results.
One of the largest was a French multicenter prospective study which evaluated FOLFIRINOX in 77 patients with unresectable LAPC (arterial invasion in 65% of cases and venous invasion in 66%). The median number of cycles received was 5. The disease control rate was 84%, PFS at 1 year was 59%, and the objective response rate was 28% [4] . Secondary resection was performed in 36% of cases and 70% of patients received CRT. Toxicity was similar to that observed in MPA. Many other publications have assessed the efficacy and tolerability of FOLFIRINOX in LAPC patients with similar results [3, [21] [22] [23] [24] [25] [26] [27] [28] [29] .
Very recently, these studies were meta-analyzed [5] in a paper pooling 13 studies with 355 LAPC patients treated by FOLFIRINOX. The median OS was 24.2 months (10-32.7 months), which is longer than what has been reported with gemcitabine (6-13 months) [11, 30] . Median PFS was 15.0 months (3-20.4 months). In eight studies reporting post-FOLFIRINOX treatments, 57% of patients received radiotherapy or CRT after FOLFIRINOX, and 28% of patients (0-43%) underwent resection after FOLFIRINOX in 12 studies reporting those data. The pooled proportion of patients who had resection was 25.9% throughout the meta-analysis population, including 78.4% R0 resections. No deaths were attributed to FOLFIRINOX toxicity.
Considering these promising results, FOLFIRINOX followed by CRT seems to be a good therapeutic sequence in LAPC. A trial that compares induction chemotherapy by FOLFIRINOX to gemcitabine with the addition of a possible consolidation CRT in both arms (investigators' decision) (NCT01926197) is currently accruing.
It is presently unclear whether increased survival is related to the ability of FOLFIRINOX to downstage tumors significantly and allow for eventual resection, or is only due to greater efficacy of this regimen in micrometastatic disease. Prospective studies are now needed to identify which patients might benefit from CRT and/or resection after FOLFIRINOX, or should continue maintenance chemotherapy.
Metastatic disease First-line treatment
Non-gemcitabine-based regimens. In 1996, Glimelius et al. [31] showed that 5-fluorouracil (5FU) chemotherapy could improve quality of life with a limited benefit in survival in advanced pancreatic cancers. Burris et al. [30] showed 1 year later that gemcitabine conferred a modest survival advantage over 5FU bolus (median overall survival of 5.6 versus 4.4 months, P ¼ 0.002) and improvement in a clinical benefit score assessing pain, Karnofsky PS, and weight. Consequently, gemcitabine became a global standard treatment of MPA.
Besides that, chemotherapy regimens without gemcitabine were also investigated. In Japan, oral fluoropyrimidine S-1 (a combination of tegafur, gimeracil, and oteracil) was not inferior to gemcitabine in terms of overall survival, had a good tolerability profile in LAPC and MPA patients [32] , and was approved for first-line treatment.
Promising results were initially reported with the combination of 5FU plus cisplatin and irinotecan in phase III and II trials [33, 34] . But other regimens such as capecitabine plus oxaliplatin, LV5FU2 plus cisplatin [35, 36] , or oxaliplatin combined with infusional 5FU [37] failed to improve outcome in MPA patients in first-line randomized trials until the ASCO 2010 annual meeting, when the results of the PRODIGE 4 trial were communicated.
This trial compared the FOLFIRINOX regimen-a combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin-with gemcitabine in first-line treatment for MPA with normal serum bilirubin levels and good PS [20] . FOLFIRINOX was the first regimen that showed a significant improvement over gemcitabine in terms of median OS (11.1 months versus 6.8 months, HR ¼ 0.57, P < 0.001) and PFS (6.4 months versus 3.3 months, HR ¼ 0.47, P < 0.001). Objective response rate (ORR) was also improved in the FOLFIRINOX arm (investigator-assessed response was 31.6% versus 9.4%, P < 0.001). Grade 3 or 4 toxicities were statistically more frequent in the experimental group (diarrhea 12.7 versus 1.8%, vomiting 14.5 versus 8.3%, fatigue 23.6 versus 17.8%, neutropenia 45.7 versus 21%, and febrile neutropenia 5.4 versus 1.2%), but were considered manageable and associated with global quality of life preservation, and FOLFIRINOX emerged as a new standard of care for MPA.
A French trial (PRODIGE 35-PANOPTIMOX) is currently comparing FOLFIRINOX given as in PRODIGE 4, FOLFIRINOX followed by LV5FU2 in a 'stop and go' strategy, and a sequential strategy of gemcitabine followed by FOLFIRI-3, which has also been shown to be superior to gemcitabine in a recently published randomized phase II trial [38] . Table 2 summarizes clinical trials that have investigated nongemcitabine-based regimens in MPA patients.
Gemcitabine-based regimens. The pharmacokinetic modulation of gemcitabine and the combination of gemcitabine with other cytotoxic drugs, as 5FU [39] , cisplatin [40, 41] , irinotecan [42] , oxaliplatin [43] , and capecitabine [44] , has shown no significant survival advantage as compared to gemcitabine alone [45] .
However, two meta-analyses showed that there was a significant improvement in OS in favor of the gemcitabinecapecitabine regimen (HR ¼ 0.86, [0.75-0.98]; P ¼ 0.02) [46] or gemcitabine plus a platinum analog (cisplatin or oxaliplatin) (HR ¼ 0.85, [0.76-0.96]; P ¼ 0.010) [47] , over gemcitabine alone, albeit with increased toxicity in the experimental arms.
Recent advances include nab-paclitaxel, an albumin-bound nanoparticle linked with paclitaxel which has shown antitumor activity as a single agent and synergistic activity in combination with gemcitabine in preclinical studies of MPA, and in particular increases the intratumoral concentration of gemcitabine [48, 49] . Nab-paclitaxel plus gemcitabine was investigated in a phase III trial in 861 patients with a Karnofsky PS score of 70 or more [50] , and significantly improved OS (primary end point: 8.5 months versus 6.7 months; HR¼ 0.72; P < 0.001), PFS (5.5 months versus 3.7 months, HR ¼ 0.69; P < 0.001), and ORR (centrally assessed response rate: 23% versus 7%; P < 0.001) compared to gemcitabine alone. The most common grade 3 or 4 adverse events were neutropenia (38% versus 27%), fatigue (17% versus 7%), and peripheral neuropathy (17% versus 1%). Two years after the advent of the FOLFIRINOX regimen, the nab-paclitaxel plus gemcitabine combination emerged as a second option for the first-line treatment of MPA.
It remains to be determined which subgroup of patients has a particular benefit from which of the two standard first-line treatment options. A recent genomic study suggested that a subgroup of patients with pancreatic cancer showing a mutational signature of DNA damage repair deficiency may benefit particularly from platinum-based chemotherapy [51] . In parallel, expression of human equilibrative nucleoside transporter 1 (hENT1), a transmembrane transporter of gemcitabine into cells, has been suggested as a predictive marker of gemcitabine efficacy [52] . These potential biomarkers still need to be assessed in a prospective clinical validation study.
A lipid-drug conjugate of gemcitabine, named CO-101, was designed to enter cells independently of hENT1 and was compared to gemcitabine in a randomized phase II trial of 367 patients with MPA [53] . An hENT1 cutoff value was defined and a high/low cutoff was applied. 65% of patients were hENT1 low. CO-101 was not superior to gemcitabine in patients with low hENT1 tumor expression (median OS: 5.7 months and 6.1 months, respectively; HR¼ 0.994; [0.746-1.326]) or in the overall study population.
A second study also seeking a synergistic association with gemcitabine was recently performed. Hypoxia is a prominent feature of the tumor microenvironment of pancreatic tumors and emerged as an important target for therapy of MPA. Evofosfamide (TH-302) is a prodrug activated by hypoxia. Despite encouraging signals, evofosfamide failed to improve OS significantly when added to gemcitabine (8.7 and 7.6 months, respectively; HR¼ 0.84; P ¼ 0.059) in previously untreated LAPC or MPA in the randomized phase III MAESTRO trial [54] . Given these results, the development of evofosfamide has been stopped in this indication. Table 3 summarizes clinical trials testing gemcitabine-based regimens in MPA patients.
The sequential strategy
Given the limited chemosensitivity of PA, an original approach was designed to improve efficacy and minimize toxicity. The idea was to combine three effective drugs, without known crossresistance, in a sequential treatment strategy alternating gemcitabine and an intensified 5FU-irinotecan combination (FOLFIRI-3) every 2 months. This sequential treatment was compared to gemcitabine alone in a randomized phase II trial [38] . The FOLFIRI-3 regimen previously showed promising ORR, PFS, and OS in a phase II first-line study [34] . The primary end point was reached in the sequential arm with a 6-month PFS rate of 43.5%, but not in the control arm (26.1%). ORR (36.7% versus 10.2%) and OS (11.0 months versus 8.2 months, HR ¼ 0.71) were also better with the sequential strategy than with gemcitabine alone. Grade 3-4 toxicities per patient in experimental/standard arms were diarrhea 12.2/0%, nausea-vomiting 8.2/4.1%, neutropenia 49.0/24.5%, and febrile neutropenia 4.1/0%. Thus, the FIRGEM strategy appeared to be promising and feasible in this patient population and is currently being evaluated in phase II-III trials including contemporary chemotherapy regimens as FOLFIRINOX (in the PRODIGE 35-PANOPTIMOX study) and gemcitabine plus nab-paclitaxel (in the PRODIGE 37-FIRGEMAX study), a randomized study comparing sequential gemcitabine plus nab-paclitaxel and FOLFIRI-3 to gemcitabine plus nab-paclitaxel. This therapeutic sequence may decrease taxane-related neurotoxicity (nab-paclitaxel dose was reduced in 41% of patients in MPACT), optimize dose intensity, and lead to a greater efficacy. These two trials are fully recruited and the first results should be presented in late 2017.
Combinations with targeted therapies
The last decade has been marked by the advent of targeted therapies in metastatic gastrointestinal cancers that increase survival and lead to a more personalized treatment in some diseases. Logically, targeted therapies have also been tested in MPA. AntiEGFRs [55, 56] , anti-angiogenics [57] [58] [59] [60] [61] as other targeted agents such as tipifarnib, an oral farnesyltransferase inhibitor [62] , trametinib [63] a MEK inhibitor, everolimus targeting the mTOR-PI3K-AKT [64] , vismodegib targeting the hedgehog pathway [65] , ruxolitinib a JAK 1-2 inhibitor [66] , and simtuzumab acting on LOXL2 enzyme (lysyl oxidase like 2) [67] have all shown disappointing results. Table 4 summarizes clinical trials that have investigated targeted therapies in MPA patients.
Second-line treatment
Historically, few studies have assessed second-line chemotherapy in MPA. The recent increase of survival and the clinical benefit offered by new first-line treatments have made second-line chemotherapy possible for substantially more patients, and clinical research for second-line treatment has been boosted during the last decade.
FOLFIRINOX or gemcitabine plus nab-paclitaxel as second-line treatments. There is currently no established standard treatment when a patient receives FOLFIRINOX or gemcitabine plus nabpaclitaxel as first-line treatment [68] . Even when two lines of chemotherapy are planned, only 48%-61% of patients can receive a second line [20, 36, 43] . Considering the recent two available options of first-line chemotherapy, it seemed logical to test the second regimen after failure of the first one in patients able to receive a second-line treatment. This observation raises questions about treatment choice and sequence. A multicenter prospective cohort study assessed the efficacy and tolerability of nab-paclitaxel plus gemcitabine after failure of first-line FOLFIRINOX in patients with MPA [69] . This sequence seemed to be effective (median OS was 18 months since the start of first-line chemotherapy), with a manageable toxicity profile, and, among patients who progressed, 62.5% received third-line chemotherapy. Interestingly, the response to first-line FOLFIRINOX did not influence the response to nab-paclitaxel plus gemcitabine, with even significantly longer PFS with nab-paclitaxel plus gemcitabine in patients who experienced a rapid progression under FOLFIRINOX [70] . Moreover, the cumulative neurotoxicity of oxaliplatin and then taxane appeared limited and acceptable. These promising results now need to be confirmed in a prospective randomized trial. Ongoing studies are testing FOLFIRINOX after nab-paclitaxel plus gemcitabine failure, but no results have been published to date. However, FOLFIRINOX has been tested in two retrospective studies, with an OS of about 8.5 months [71, 72] .
Oxaliplatin or irinotecan combined with 5FU regimen. Before the PRODIGE 4 trial, some phase II trials yielded encouraging results with oxaliplatin plus 5FU using various doses and schedules as rescue chemotherapy for gemcitabine-refractory pancreatic cancer [73, 74] , especially the FOLFOX regimen [75] [76] [77] . A randomized phase II study of modified FOLFIRI-3 versus modified FOLFOX for patients previously treated with gemcitabine showed 6-month survival rates of 27% and 30%, respectively, and both regimens were well tolerated [78] .
More recently, a phase III trial showed that the 5FU plus oxaliplatin (OFF regimen) was superior to 5FU [79] , suggesting that this combination may be a standard second-line treatment for MPA. However, the PANCREOX phase III study [80] assessed in 108 MPA patients previously treated with gemcitabine the benefit of mFOLFOX6 versus infusional 5FU plus leucovorin in this setting and gave different results. PFS was similar in both arms (median 3.1 versus 2.9 months, P ¼ 0.99) and OS was inferior in patients assigned to FOLFOX-6, possibly due to the higher use of third-line regimens in the 5-FU/LVF arm. On the other hand, increased toxicities were observed with the addition of oxaliplatin. In summary, the beneficial role of oxaliplatin-5FU combinations in second-line treatment of MPA is not yet confirmed.
Nanoliposomal irinotecan. Nanoliposomal irinotecan comprises irinotecan free base encapsulated in liposome nanoparticles, which protect irinotecan in the circulation against conversion to its active metabolite (SN-38), thus increasing and prolonging intratumoral levels of both irinotecan and SN-38 [81] . After a promising phase II study [82] the NAPOLI-1 phase III trial [83] compared, in patients previously treated with gemcitabine-based therapy, nanoliposomal irinotecan (MM-398 or NALIRI) alone, 5FU and folinic acid alone and the combination of both therapies. The combination of NALIRI and 5FU was more effective than 5FU alone or NALIRI alone (median OS of 6.1 versus 4.2 and 4.9 months, respectively [HR: 0.67; P ¼ 0.012]). But grade 3 or 4 adverse events also occurred more frequently in the NALIRI plus 5FU arm, neutropenia (27%), diarrhea (13%), vomiting (11%), and fatigue (14%) being the most common side effects.
Though we still lack data comparing NALIRI to irinotecan monotherapy, NALIRI plus 5FU and folinic acid is emerging as a second-line option in MPA and has led to FDA and EMA approval for nanoliposomal irinotecan this year.
A recent comparative systematic review of the four randomized trials evaluating oxaliplatin-or irinotecan-based therapies in patients with MPA previously treated with gemcitabine [84] , has demonstrated significant dissimilarity across trials that did not conduct an indirect treatment comparison. Further studies are thus needed in the second-line setting, but also with predetermined first-and second-line treatment, as the first-line choice directly impacts the second-line treatment decision. Table 5 summarizes clinical trials performed in the second-line setting in MPA patients.
Future perspectives
After the results of the NAPOLI trial, a phase I/II study is currently investigating three arms in first-line treatment: nanoliposomal irinotecan plus 5FU, a FOLFIRINOX regimen with nanoliposomal irinotecan replacing standard irinotecan, and nab-paclitaxel plus gemcitabine (NCT02551991).
PEGPH20, a recombinant human hyaluronidase enzyme that degrades stromal hyaluronan accumulated around tumor cells, is currently the subject of a phase II study in combination with gemcitabine and nab-paclitaxel in previously untreated MPA. An interim analysis indicated a good tolerability profile and increased PFS when hyaluronan was highly expressed in the tumors [85] . A phase I-II trial (NCT01959139) is currently assessing hyaluronan in combination with FOLFIRINOX.
Ibrutinib is a first-in-class, oral, once-daily therapy that inhibits Bruton's tyrosine kinase (BTK), a key signaling molecule in the B-cell receptor signaling complex that plays an important role in the survival and spread of malignant B cells [86] . A clinical trial of ibrutinib plus gemcitabine or gemcitabine plus nab-paclitaxel, evaluating safety, then efficacy and including correlative studies is currently ongoing (NCT02562898, phase II-III)
Demcizumab, an anti-DLL4 (DLL4 is a ligand of Notch receptors) monoclonal antibody, has shown a promising response rate (41%) in a pilot trial, with a good safety profile in combination with gemcitabine and nab-paclitaxel, and is currently being investigated in a phase II study (NCT02289898). A phase II trial with tarextumab (another anti-Notch 2-3 receptor) has also recently closed recruitment and the first results are expected in 2017.
In immunotherapy studies, although PD-L1 or PD-L2 is expressed in about 2/3 of MPA cases [87] , no objective response in 14 patients with pancreatic cancer was observed in a phase I trial testing an anti-PD-L1 antibody BMS-936559 [88] or in a phase II study of anti-CTL4 ipilimumab [89] .
GVAX, a vaccine composed of whole tumor cells expressing granulocyte macrophage colony-stimulating factor, stimulates recruitment of dendritic cells, which phagocytize tumor cells and present tumor antigens to T lymphocytes. In a randomized phase II trial, GVAX prolonged survival of MPA patients, with minimal toxicity in previously treated patients (6.1 months versus 3.9 months, P ¼ 0.02) [90] . GVAX could also secondarily increase the expression of PD-1 and PD-L1 and thereby sensitivity to immune checkpoint inhibitor. A study evaluating anti-PD1 therapy combined with GVAX in murine models showed promising results, which need to be confirmed in humans [91] . However, a phase III trial has shown frontline negative results with another telomerase peptide vaccine (GV 1001) for pretreated patients [92] . An ongoing phase I study is testing a combination of mogamulizumab (anti-CCR4) plus MEDI4736 (anti-PD-L1) and combination of mogamulizumab plus tremelimumab (anti-CTLA-4). Table 6 sumarizes ongoing trials in MPA.
Conclusion
To conclude, patients with LAPC should be treated in clinical trials as often as possible. In routine practice, if inclusion in a clinical trial is not possible, gemcitabine chemotherapy is currently the recommended standard [19] . However, FOLFIRINOX seems promising and current clinical trials are seeking to confirm its superiority to gemcitabine. Erlotinib does not add anything besides side effects to gemcitabine. Consolidation CRT does not seem to improve PFS or OS in unselected patients with LAPC, but may remain valuable in a subgroup that still needs to be defined, and new radiation techniques still need to be evaluated in this setting. Secondary resection is probably an accessible goal for a significant proportion of patients with LAPC responding to induction therapy. In the metastatic setting, one of the major problems is that so many patients at diagnosis are unfit for chemotherapy. Early diagnosis strategies, to increase access to chemotherapy before global PS degradation, are of major importance and warrant specific health programs. Intensified first-line regimens such as FOLFIRINOX should generally be favored, but frail patients, those over 80 years old, PS 2 patients, and patients with high serum bilirubin may be not eligible for this regimen. In these cases, gemcitabine plus nab-paclitaxel in fit patients or gemcitabine alone for the others is the preferred choice.
Ideally, we would use predictive biomarkers, as in other solid tumors, to tailor treatments to individual patients. However, no biomarker has yet been validated in MPA. The value of hENT1 expression [52, 54, 93] in predicting gemcitabine efficacy is controversial, and secreted protein acidic and rich in cysteine, which seemed promising in predicting the efficacy of nab-paclitaxel, was not validated in the pivotal MPACT trial in MPA. Decrease of ERCC-1-mediated DNA repair or deficient mismatch repair status is another emerging molecular feature in MPA that may help to identify patients who will benefit from first-line platinum-containing chemotherapy [51] .
Rather than head-to-head comparisons of current first-line standard treatments, in the near future we need to compare treatment sequences in large multinational strategic trials, if we are to improve patient outcomes. We should in parallel increase the number and quality of translational research projects in the field of pancreatic cancer to identify and validate relevant prognostic and predictive biomarkers, so as to improve individualization of treatment.
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